Genetic variation in the cytochrome P450 epoxygenase pathway and cardiovascular disease risk

Pharmacogenomics

Volumn 8, Issue 10, 2007, Pages 1369-1383

  Theken, Katherine N ^a   Lee, Craig R ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Arachidonic acid; Atherosclerosis; Cardiovascular disease; CYP2C8; CYP2C9; CYP2J2; EETs; EPHX2; Polymorphism; Soluble epoxide hydrolase

Indexed keywords

ARACHIDONIC ACID; CYTOCHROME P450; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2J2; CYTOCHROME P450 EPOXYGENASE; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; UNCLASSIFIED DRUG;

ANGIOCARDIOGRAPHY; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CATALYSIS; CEREBROVASCULAR DISEASE; CORONARY ARTERY OBSTRUCTION; DISEASE COURSE; ENZYME ACTIVITY; EPOXIDATION; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEART CATHETERIZATION; HIGH RISK PATIENT; HUMAN; HYDROLYSIS; HYPERTENSION; IMMUNOMODULATION; IN VIVO STUDY; ISCHEMIC HEART DISEASE; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; PATHOGENESIS; POPULATION RESEARCH; PREVALENCE; PROMOTER REGION; REVIEW; RISK ASSESSMENT; VASODILATATION;

ARACHIDONIC ACID; ARYL HYDROCARBON HYDROXYLASES; CARDIOVASCULAR DISEASES; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; OXIDATION-REDUCTION; OXYGENASES; RISK FACTORS; VARIATION (GENETICS);

EID: 36448993993     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.10.1369     Document Type: Review

References (73)

1. Rendic S, Di Carlo FJ: Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev. 29, 413-580 (1997).
2. Brash AR: Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J. Biol. Chem. 274, 23679-23682 (1999)
3. Kuehl FA Jr, Egan RW: Prostaglandins, arachidonic acid, and inflammation. Science 210, 978-984 (1980).
4. Smith WL, Garavito RM, DeWitt DL: Prostaglandin endoperoxide H synthases (cyclooxygenases) -1 and -2. J. Biol. Chem. 271, 33157-33160 (1996).
5. Roman RJ: P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol. Rev. 82, 131-195 (2002).
6. Zeldin DC: Epoxygenase pathways of arachidonic acid metabolism. J. Biol. Chem. 276, 36059-36062 (2001).
7. Enayetallah AE, French RA, Thibodeau MS, Grant DF: Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8. 2C9, and 2J2 in human tissues. J. Histochem. Cytochem. 52, 447-454 (2004).
8. Node K, Huo Y, Ruan X et al.: Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285, 1276-1279 (1999).
9. Larsen BT, Miura H, Hatoum OA et al.: Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition. Am. J. Physiol. Heart Circ. Physiol. 290, H491-499 (2006).
10. Campbell WB, Gebremedhin D, Pratt PF, Harder DR: Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ. Res. 78, 415-423 (1996).
11. Fisslthaler B, Popp R, Kiss L et al.: Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 401, 493-497 (1999).
12. Liu Y, Zhang Y, Schmelzer K et al.: The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids. and soluble epoxide hydrolase. Proc. Natl Acad. Sci. USA 102, 16747-16752 (2005).
13. Schmeizer KR, Kubala L. Newman JW, Kim IH, Eiserich JP, Hammock BD: Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc. Natl Acad. Sci. USA 102, 9772-9777 (2005).
14. Seubert J. Yang B, Bradbury JA et al.: Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway. Circ. Res. 95, 506-514 (2004).
15. Seubert JM, Sinal CJ, Graves J et al.: Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ. Res. 99, 442-450 (2006).
16. Dorrance AM, Rupp N, Pollock DM, Newman JW, Hammock BD, Imig JD: An epoxide hydrolase inhibitor, 12-(3-adamantan- 1 -y1-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 46, 842-848 (2005).
17. Koerner IP, Jacks R, DeBarber AE et al.. Polymorphisms in the human soluble epoxide hydrolase gene EPHX2 linked to neuronal survival after ischemic injury. J. Neurosci. 27, 4642-4649 (2007).
18. Node K, Ruan XL, Dai J et al.: Activation of G alphas mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids. J. Biol. Chem. 276, 15983-15989(2001).
19. Munzenmaier DH, Harder DR: Cerebral microvascular endothelial cell tube formation: role of astrocytic epoxyeicosatrienoic acid release. Am. J. Physiol. Heart Circ. Physiol. 278, H1163-1167 (2000).
20. Sun J. Sui X, Bradbury JA, Zeldin DC, Conte MS, Liao JK: Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids. Circ. Res. 90, 1020-1027 (2002).
21. Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, Gonzalez FJ: Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J. Biol. Chem. 275, 40504-40510, (2000).
22. Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD: Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension.
23. Imig JD, Zhao X, Zaharis CZ et al.: An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension 46, 975-981 (2005).
24. de Winther MP, Kanters E, Kraal G, Hofker MH: Nuclear factor κB signaling in atherogenesis. Arterioscler. Thromb. Vasc. Biol. 25, 904-914 (2005).
25. Cowart LA, Wei S, Hsu MH et al.: The CYP4A isoforms hydroxylate epoxyeicosatrienoic acids to form high affinity peroxisome proliferator-activated receptor ligands. J. Biol. Chem. 277, 35105-35112 (2002).
26. Wu S, Moomaw CR, Tomer KB, Falck JR, Zeldin DC: Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J. Biol. Chem. 271. 3460-3468 (1996).
27. Gaedigk A, Baker DW, Totah RA et al.: Variability of CYP2J2 expression in human fetal tissues. J. Pharmacol. Exp. Ther. 319, 523-532 (2006).
28. King LM, Ma J, Srettabunjong S et al.: Cloning of CYP2J2 gene and identification of functional polymorphisms. Mol. Pharmacol. 61, 840-852 (2002).
29. Lee SS, Jeong HE, Liu KH et al.: Identification and functional characterization of novel CYP2J2 variants: G312R variant causes loss of enzyme catalytic activity. Pharmacogenet. Genomics 15, 105-113 (2005).
30. Yamazaki H, Okayama A, Imai N, Guengerich FP, Shimizu M: Inter-individual variation of cytochrome P4502J2 expression and catalytic activities in liver microsomes from Japanese and Caucasian populations. Xenobiotica 36, 1201-1209 (2006).
31. Spiecker M, Darius H, Hankein T et al.: Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation 110, 2132-2136 (2004).
32. Liu PY, Li YH, Chao TH et al.: Synergistic effect of cytochrome P450 epoxygenase CYP2J2*7 polymorphism with smoking on the onset of premature myocardial infarction. Atherosclerosis (2006) (Epub ahead of print).
33. Spiecker M, Zeldin DC, Mugge A, Tenderich G, Liao JK, Milting H: Reduced human myocardial mRNA expression of CYP2J2 in individuals with the G-50T promoter polymorphism. American Heart Association Scientific Sessions. Chicago, USA, Circulation 691, II-117 (2006).
34. Hoffmann MM, Bogert P, Seelhorst U et al.: The -50G>T polymorphism in the promoter of the CYP2J2 gene in coronary heart disease: the Ludwigshafen Risk and Cardiovascular Health study. Clin. Chem. 53, 539-540 (2007).
35. Lee CR, North KE, Bray MS, Couper DJ, Heiss G, Zeldin DC: CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) study. Pharmacogenet. Genomics 17, 349-358 (2007).
36. King LM, Gainer JV, David GL et al.: Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension. Pharmacogenet. Genomics 15, 7-13 (2005).
37. Wu SN, Zhang Y, Gardner CO et al.: Evidence for association of polymorphisms in CYP2J2 and susceptibility to essential hypertension. Ann. Hum. Genet. 71, 519-525 (2007).
38. Dreisbach AW, Japa S, Sigel A et al.: The Prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension. Am. J. Hypertens. 18, 1276-1281 (2005).
39. Pucci L, Lucchesi D, Chiruili V et al.: Cytochrome P450 2J2 polymorphism in healthy Caucasians and those with diabetes mellitus. Am. J. Pharmacogenomics. 3, 355-358 (2003).
40. Goldstein JA, de Morais SM: Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4, 285-299 (1994).
41. Klose TS, Blaisdell JA, Goldstein JA: Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. J. Biochem. Mol. Toxicol. 13, 289-295 (1999).
42. Yasar U, Lundgren S, Eliasson E et al.: Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem. Biophys. Res. Commun. 299, 25-28 (2002).
43. Totah RA, Rettie AE: Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin. Pharmacol. Ther. 77, 341-352 (2005).
44. Lee CR, Goldstein JA, Pieper JA: Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in vitro and human data. Pharmacogenetics 12, 251-263 (2002).
45. Bahadur N, Leathart JB, Mutch E et al.: CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomes. Biochem. Pharmacol. 64, 1579-1589 (2002).
46. Dai D, Zeldin DC, Blaisdell JA et al.: Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11, 597-607 (2001).
47. Soyama A, Saito Y, Hanioka N et al.: Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism. Biol. Pharm. Bull. 24, 1427-1430 (2001).
48. Lundblad MS, Stark K, Eliasson E, Oliw E, Rane A: Biosynthesis of epoxyeicosatrienoic acids varies between polymorphic CYP2C enzymes. Biochem. Biophys. Res. Commun. 327, 1052-1057 (2005).
49. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR: Impaired S-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 4, 39-42 (1994).
50. Sullivan-Klose TH, Ghanavem BI, Bell DA et al.: The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6, 341-349 (1996).
51. Yasar U, Bennet AM, Eliasson E et al.: Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. Pharmacogenetics 13, 715-720 (2003).
52. Visser LE, van Schalk RH, Jan Danser AH et al.: The risk of myocardial infarction in patients with reduced activity of cytochrome P450 2C9. Pharmacogenet. Genomics 17, 473-479 (2007).
53. Newman JW, Morisseau C, Harris TR, Hammock BD: The soluble epoxide hydrolase encoded by EPXH2 is a bifunctional enzyme with novel lipid phosphate phosphatase activity. Proc. Natl Acad. Sci. USA 100, 1558-1563 (2003).
54. Sandberg M, Meijer J: Structural characterization of the human soluble epoxide hydrolase gene (EPHX2). Biochem. Biophys. Res. Commun. 221, 333-339 (1996).
55. Srivastava PK, Sharma VK, Kalonia DS, Grant DF: Polymorphisms in human soluble epoxide hydrolase: effects on enzyme activity, enzyme stability, and quaternary structure. Arch. Biochem. Biophys. 427, 164-169 (2004).
56. Przybyla-Zawislak BD, Srivastava PK, Vazquez-Matias J et al.: Polymorphisms in human soluble epoxide hydrolase. Mol. Pharmacol. 64, 482-490 (2003).
57. Sandberg M, Hassett C, Adman ET, Meijer J, Omieciriski CJ: Identification and functional characterization of human soluble epoxide hydrolase genetic polymorphisms. J. Biol. Chem. 275, 28873-28881 (2000).
58. Lee CR, North KE, Bray MS et al.: Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. Hum. Mol. Genet. 15, 1640-1649 (2006).
59. Fornage M, Boerwinkle E, Doris PA, Jacobs D, Liu K, Wong ND: Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects: the Coronary Artery Risk Development in Young Adults (CARDIA) study. Circulation 109, 335-339 (2004).
60. Wei Q, Doris PA, Pollizotto MV et al.: Sequence variation in the soluble epoxide hydrolase gene and subclinical coronary atherosclerosis: interaction with cigarette smoking. Atherosclerosis 190, 26-34 (2007).
61. Fornage M, Lee CR, Doris PA et al.: The soluble epoxide hydrolase gene harbors sequence variation associated with susceptibility to and protection from incident ischemic stroke. Hum. Mol. Genet. 14, 2829-2837 (2005).
62. Sato K, Emi M, Ezura Y et al.: Soluble epoxide hydrolase variant (Glu287Arg) modifies plasma total cholesterol and triglyceride phenotype in familial hypercholesterolemia: intrafamilial association study in an eight-generation hyperlipidemic kindred. J. Hum. Genet. 49, 29-34 (2004).
63. Ohtoshi K, Kaneto H, Node K et al.: Association of soluble epoxide hydrolase gene polymorphism with insulin resistance in Type 2 diabetic patients. Biochem. Biophys. Res. Commun. 331, 347-350 (2005).
64. Chanock SJ, Manolio T, Boehnke M et al.: Replicating genotype-phenotype associations. Nature 447, 655-660 (2007).
65. Colhoun HM, McKeigue PM, Davey Smith G: Problems of reporting genetic associations with complex outcomes. Lancet 361, 865-872 (2003).
66. Zondervan KT, Cardon LR: The complex interplay among factors that influence allelic association. Nat. Rev. Genet. 5, 89-100 (2004).
67. Sayed-Tabatabaei FA, Oostra BA, Isaacs A, van Duijn CM, Witteman JC: ACE polymorphisms. Circ. Res. 98, 1123-1133 (2006).
68. Casas JP, Cavalleri GL, Bautista LE, Smeeth L, Humphries SE, Hingorani AD: Endothelial nitric oxide synthase gene polymorphisms and cardiovascular disease: a HuGE review. Am. J. Epidemiol. 164, 921-935 (2006).
69. Brodde OE, Bruck H, Leineweber K: Cardiac adrenoceptors: physiological and pathophysiological relevance. J. Pharmacol. Sci. 100, 323-337 (2006).
70. Kawashima S, Yokoyama M: Dysfunction of endothelial nitric oxide synthase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 24, 998-1005 (2004).
71. Ambrose JA, Barua RS: The pathophysiology of cigarette smoking and cardiovascular disease: an update. J. Am. Coll. Cardiol. 43, 1731-1737 (2004).
72. Imig JD: Cardiovascular therapeutic aspects of soluble-epoxide hydrolase inhibitors. Cardiovasc. Drug Rev. 24, 169-188 (2006).
73. The ARIC Investigators: The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am. J. Epidemiol. 129, 687-702 (1989).